EMERYVILLE, Calif., May 19, 2023 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable…
Under the terms of the agreement, Amyris will manufacture and supply squalene to Croda and Croda will license squalene technology from Amyris to market, distribute, and sell squalene as an excipient, or as an ingredient in formulated products for use in human and veterinary vaccines, drug delivery systems, or nucleic acid delivery systems. In addition to an upfront payment of $4 million and a future – performance based – milestone payment of $4 million, Amyris will receive a share of profits generated from the sale of squalene excipients and formulated products incorporating Amyris’ squalene technology for use in the vaccine field.
